Pfizer Corporation Hong Kong Limited 美國輝瑞科研製藥

Content

Clindamycin phosphate^1-3

Indication

Treatment of acne vulgaris ^1-3

Clinical Evidence

Clindamycin has been shown to:

Have in vitro activity against all isolates of Propionibacterium acnes^1,2
Provide significant reduction in skin surface and follicular Propionbacterium spp and Micrococcaceae in mild to moderate acne vulgaris⁴
Be effective in papulopustular acne grade I-II, particularly with marked inflammation⁵
Be as effective as the topical antibiotics tetracycline and erythromycin⁵

Safety Profile¹

VERY COMMON and COMMON ADVERSE EVENTS: Skin dryness, abdominal pain, skin irritation, gastrointestinal disturbances, contact dermatitis, stinging in the eyes, Gram-negative folliculitis or skin oiliness^1-3

INTERACTIONS: Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.²

Dosages

Apply a thin film to affected area of clean and dry skin twice daily.^1-3

Strengths

Topical Solution 1%, Topical Gel 1%, Topical Lotion 1 %^1-3

Packing

Topical Solution 1% x 30 mL,¹ Topical Gel 1% x 30 g,² Topical Lotion 1% x 30 mL³

Important Safety Information¹

CONTRAINDICATIONS: Hypersensitivity to clindamycin or lincomycin, a history of regional enteritis, ulcerative colitis or antibiotic-related colitis^1-3

SPECIAL PRECAUTIONS: When applied topically, the physician should be alert to the remote possibility of an antibiotic induced severe diarrhea. Significant diarrhea (which theoretically may occur up to several weeks post-therapy) should be managed as if antibiotic-associated. Do not apply to eyes, mucosa, or to open skin lesions or skin conditions affecting the site of application. Alcohol base may cause burning and irritation of the eyes. For dry or sensitive skin, it is better to use the topical lotion rather than the topical solution. Concomitant use of Dalacin T® with other available acne preparations (eg, benzoyl peroxide and retinoic acid) must be done with caution. ^1-3

COMMON ADVERSE EVENTS: Skin dryness, abdominal pain, skin irritation, gastrointestinal disturbances, contact dermatitis, stinging in the eyes, Gram-negative folliculitis or skin oiliness^1-3

PREGNANCY and LACTATION: Dalacin T® should not be used during pregnancy or breastfeeding.^1-3

Please refer to the full prescribing information for more safety information

References

1. Dalacin T® Solution (clindamycin phosphate) Prescribing Information. Pfizer Corporation Hong Kong Limited. Version Date: October 2007.

2. Dalacin T® Gel (clindamycin) Prescribing Information. Pfizer Corporation Hong Kong Limited. Version Date: June 2007.

3. Dalacin T® Lotion (clindamycin) Prescribing Information. Pfizer Corporation Hong Kong Limited. Version Date: December 2010.

4. Cunliffe WJ, Fernandez C, Bojar R, et al. An observer-blind parallel-group, randomized, multicentre clinical and microbiological study of a topical clindamycin/zinc gel and a topical clindamycin lotion in patients with mild/moderate acne. J Dermatolog Treat. 2005;16(4):213-218.

5. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J Dtsch Dermatol Ges. 2006;4(4):293-300.

Please review the full product information or package insert before prescribing.

DAL11001P